Introduction
============

B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most frequent cancer in children.^[@b1-1041176]^ Current 5-year survival rates in pediatric BCP-ALL approach 90%. However, BCP-ALL in infants (iBCP-ALL; \<1 year of age) remains clinically challenging with an aggressive early clinical presentation in uniquely vulnerable hosts.^[@b2-1041176]^ Approximately 80% of iBCP-ALL are diagnosed with chromosomal rearrangements involving the mixed-lineage leukemia (*KMTA2*, also called *MLL*) gene, located on 11q23,^[@b3-1041176]--[@b5-1041176]^ which confers a dismal prognosis especially in patients carrying the t(4;11)/KMT2A-AFF1^+^ (MLL-AF4^+^).^[@b6-1041176]--[@b8-1041176]^

*MLL* is a H3K4 histone methyltransferase required for normal hematopoiesis and *HOX* gene expression.^[@b9-1041176],[@b10-1041176]^ Leukemia transformation by *MLL* fusions requires the recruitment of the H3K79 histone methyltransferase Dot1L to the MLL transcriptional complex.^[@b11-1041176],[@b12-1041176]^ Indeed, an H3K79 methylation profile defines both mouse and human t(4;11)/MLL-AF4^+^ BCP-ALL.^[@b13-1041176]^ Importantly, *MLL* rearrangements (*MLLr*) occur prenatally during embryonic/fetal hematopoiesis, and the concordance rate for iBCP-ALL in identical twins with a monochorionic placenta is close to 100%.^[@b14-1041176]--[@b17-1041176]^ This, coupled to the extremely short latency, suggests that *MLL* fusions might be sufficient for leukemogenesis.^[@b4-1041176]^ Accordingly, genome-wide studies using both single nucleotide polymorphism arrays and whole-genome sequencing revealed that *MLLr* iBCP-ALL has a very low frequency of somatic mutations with the predominant clone carrying \~1.3 non-silent mutations and one copy number alteration.^[@b18-1041176]--[@b20-1041176]^ Although these studies were performed at low coverage sequencing they reinforce the concept that *MLLr* iBCP-ALL requires few additional mutations to induce full transformation. In contrast, MLL-AF4-induced leukemogenesis has proven difficult to model.^[@b4-1041176],[@b9-1041176]^ With the exception of a recent work by Lin *et al*.^[@b21-1041176],[@b22-1041176]^ who fused human MLL to murine Af4, creating an artificial leukemogenic human-mouse chimeric fusion, current murine and humanized models of MLL-AF4^+^ BCP-ALL do not faithfully recapitulate the disease pathogenesis/phenotype, suggesting that MLL-AF4 *per se* is insufficient to initiate leukemogenesis.^[@b23-1041176]--[@b28-1041176]^

The few mutations and copy number alterations present in *MLLr* iBCP-ALL seem subclonal and not always retained at relapse.^[@b20-1041176]^ Intratumor heterogeneity drives clonal evolution in response to microenvironmental cues and cytotoxic treatment and therefore recurrent mutations at diagnosis and relapse may be found in minor but clinically relevant subclones.^[@b29-1041176]^ Here we aimed to address the clinical relevance of subclonal mutations and gene expression signatures in a large cohort of iBCP-ALL. To do this, we performed deeper exome sequencing along with whole-genome DNA- and RNA-sequencing on a large cohort of 50 MLLr and non-MLL iBCP-ALL patients uniformly treated and followed up according to an Interfant treatment protocol.^[@b30-1041176]^ Similarly to Anderson *et al*.,^[@b20-1041176]^ we report a silent mutational landscape in iBCP-ALL irrespective of the *MLL* rearrangement/status. However, strikingly, our genome-wide DNA and RNA analyses revealed new, clinically relevant information about disease outcome and cell-of-origin for t(4;11) and *RAS* mutations.

Methods
=======

Patients
--------

Bone marrow or peripheral blood samples from 124 infants (\<12 months old) diagnosed with either pro-B or pre-B-cell ALL were used in this study. The discovery cohort of patients was composed of 42 *de novo* cases: 27 with the t(4;11) encoding for MLL-AF4, five with the t(9;11) encoding for KMT2A-MLLT3 (MLL-AF9) and ten without *MLLr* (non-MLL B-other BCP-ALL without numerical or structural chromosomal abnormalities reported at diagnosis). Additionally, for eight MLL-AF4^+^ iBCP-ALL patients matched diagnostic-relapse samples were available allowing for longitudinal studies. *MLL* rearrangements were confirmed by fluorescence *in-situ* hybridization.^[@b31-1041176],[@b32-1041176]^ For validation, an additional cohort of patients, comprising 43 MLL-AF4^+^, 11 MLL-AF9^+^, and 28 non-MLL iBCP-ALL cases, was used. All patients were enrolled in the Interfant99 treatment study. Bone marrow samples were collected at Erasmus MC-Sophia Children's Hospital (Rotterdam, the Netherlands), Armand Trousseau Hospital (Paris, France), and San Gerardo Pediatric Hospital (Monza, Italy). Complete remission bone marrow samples were available for all patients. The clinical and genetic features of the patients are presented in *Online Supplementary Table S1*. As a control for the RNA-sequencing studies, CD34^+^CD19^+^ healthy B-cell progenitors were purified by fluorescence-activated cell sorting (FACS) from 22-week old human fetal livers (FL) as previously described.^[@b32-1041176]^ FL hematopoietic stem and progenitor cells (HSPC) were processed and FACS-purified from second trimester human FL as previously described.^[@b33-1041176]^ Briefly, cells were processed and stained for flow cytometry with up to ten fluorophore-conjugated monoclonal antibodies \[antibodies (clone): CD34PECy7 (8G12), CD45RA FITC (HI100), CD19APC (HIB19), CD123PE (9F5), CD90 PECy5 (5E10), CD38 Pacific blue (HIT2), lineage cocktail APC (CD2 (RPA-2.10)/CD3 (OKT3)/CD14 (61D3)/CD16(CB16)/CD19 (HIB19)/CD56 (TULY56)/CD235a (HIR2)\]. FACS was performed using a BD FACSAria II (Becton Dickinson). Gates were set with unstained and fluorescence minus one controls, on viable cells. Data were analyzed using FlowJo software (Tree Star). Gating strategies are as described in the results section. The study was approved by the Barcelona Clinic Hospital (2013/8529) and Hammersmith and Queen Charlotte's Hospital (04/Q0406/145) research ethics committees.

Statistical analysis
--------------------

For quantitative variables, a one-tailed *t*-test was used to identify significant differences between groups. For qualitative variables, a Fisher exact test was used in order to identify significant differences between groups of patients. Software for analysis of mutations and gene expression have their own statistical models explained in detailed in the references. Where multiple tests were performed the significance is shown corrected for multiple testing. Mutation allele frequency evolution was plotted with the R package distribution Fishplot. Patterns Fisher exact test was used to assess the association between clinical characteristics and presence of *RAS* mutations or AF4-MLL expression. Event-free survival was defined as time from diagnosis to first event, i.e. resistance, relapse, death from any cause, or second malignant neoplasm. Observation periods were censored at the time of last contact when no events were reported. Event-free survival curves were estimated with the Kaplan-Meier method and standard errors (SE) were calculated according to Greenwood. Differences in event-free survival and overall survival between groups were compared with the log-rank test. Analysis of the prognostic relevance of AF4-MLL/HOXA expression in combination with risk stratification according to the Interfant-06 protocol (based on age at diagnosis, white blood cell count and response to prednisone) was performed with the Cox model and the Wald test. All tests were two-sided. Analyses were performed using SAS 9.2.

DNA, RNA and B-cell receptor (VDJ) repertoire genome-wide analyses and data analysis
------------------------------------------------------------------------------------

Preparation and analysis of all DNA and RNA genome-wide high-throughput sequencing is detailed in the *Online Supplementary Methods*, *Online Supplementary Figure S1* and *Online Supplementary Table S2*.

Results
=======

At diagnosis infant B-cell precursor acute lymphoblastic leukemia shows a silent mutational landscape irrespective of *MLL* gene status
---------------------------------------------------------------------------------------------------------------------------------------

Whole-exome sequencing and whole-genome sequencing analyses showed a silent mutational landscape in the three iBCP-ALL subtypes studied here: MLL-AF4^+^, MLL-AF9^+^ and non-MLL (n=42 patients, *Online Supplementary Table S1*). Our study revealed an average of one genomic rearrangement and 2.5 non-silent single nucleotide variants, a 2-fold higher number than that reported by Andersson *et al*.,^[@b20-1041176]^ likely reflecting the 3-fold larger sequencing coverage ([Figure 1A](#f1-1041176){ref-type="fig"}, *Online Supplementary Figure S1* and *Online Supplementary Table S3*). All mutations found at diagnosis were validated using orthogonal methods. This mutational frequency is the lowest described for any other pediatric tumor type according to recent reports^[@b34-1041176]^ (*Online Supplementary Figure S2*). Intriguingly, one third of the mutations validated showed a mutant allele frequency (MAF) \<20% indicating that iBCP-ALL contains genetically different intratumoral subclones despite its genomic stability, likely explaining the higher mutational load than that reported by Andersson *et al*.^[@b20-1041176]^ ([Figure 1A](#f1-1041176){ref-type="fig"} and *Online Supplementary Table S3*). Despite the paucity of mutations, \~80% of the validated protein-coding mutations (90/116) are predicted to produce deleterious effects on the protein (*Online Supplementary Figure S3A*) which might support a strong selective pressure in iBCP-ALL. To gain insights into the molecular mechanisms underlying the accumulation of mutations, we analyzed the enrichment of specific mutational signatures as described by Alexandrov *et al*.^[@b35-1041176]^ In the MLL-AF4^+^ iBCP-ALL subgroup we identified a significant enrichment of signature 1 characterized by the accumulation of C\>T/G\>A transitions, linked to a spontaneous deamination of 5-methylcytosine (*Online Supplementary Figure S3B,C*).^[@b35-1041176]^ This mutational signature has also been described in other pediatric tumors, suggesting that iBCP-ALL is not subjected to a specific mutational signature.

![Somatic mutations detected by whole-exome sequencing in the discovery cohort of infant B-cell precursor acute lymphoblastic leukemia. (A) Total number of mutations identified in each individual patient. The total number of non-synonymous mutations (yellow area, right Y axis) and mutant allele frequency (MAF) for each mutation (individual dots, left Y axis) are represented. (B) Oncodrive software identified the PI3K-RAS pathway as the only recurrently mutated pathway in infant B-cell precursor acute lymphoblastic leukemia. The distribution of mutations in genes of the PI3K-RAS pathway is shown for all patients within the three iBCP-ALL subgroups: \[total 42 patients: 27 t(4;11)^+^, 5 t(9;11)^+^ and 10 MLLwt\].](1041176.fig1){#f1-1041176}

We also determined the molecular breakpoint of all MLLr at the base-pair level. In t(4;11)/MLL-AF4^+^ iBCP-ALL, the *AF4* breakpoints were almost invariably localized within intron 3 whereas *MLL* breakpoints were found between introns 9 and 11 (*Online Supplementary Table S4*).^[@b3-1041176]^ We found whole-genome sequencing reads compatible with an AF4-MLL reciprocal rearrangement in all samples (*Online Supplementary Figure S4*). AF4-MLL genomic breakpoints were validated by polymerase chain reaction capillary sequencing and they were located nearby MLL-AF4 breakpoints, confirming a reciprocal chromosomal translocation.

RAS-PI3K is the only recurrently mutated pathway in infant B-cell precursor acute lymphoblastic leukemia with *NRAS* mutations being significantly more frequent in t(4;11)^+^ patients
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Despite the low number of mutations found per sample, 38% of the sequenced iBCP-ALL patients displayed activating/gain-of-function mutations in either *KRAS* or *NRAS*. Additional mutations in other genes members of the RAS-PI3K pathway such as *FGFR4*, *JAK2*, *PTPN11*, *SETD2*, or *FLT3* were also identified ([Figure 1B](#f1-1041176){ref-type="fig"}). To further validate the unique recurrence of *KRAS* and *NRAS* mutations, we performed targeted sequencing of these mutations in a large, additional validation cohort of infant patients (n=82) and confirmed that 34% of the iBCP-ALL cases carry mutations in either *KRAS* or *NRAS*^[@b36-1041176]^ ([Figure 2A](#f2-1041176){ref-type="fig"}). Interestingly, the overall frequency of RAS mutations differed slightly between the different cytogenetic subgroups of iBCP-ALL, with the MLL-AF4^+^ subgroup showing the highest frequency (42%) and the MLL-AF9^+^ subgroup the lowest (19%). This difference was basically attributed to the frequency of *NRAS* mutations, which was 6-fold more common in the MLL-AF4^+^ subgroup (32% *vs*. 6%, Fisher exact test *P*=0.01) ([Figure 2A,B](#f2-1041176){ref-type="fig"}).

![Frequent somatic mutations in *RAS* genes in both the discovery and validation cohorts. (A) Specific *KRAS* and *NRAS* mutations recurrently found in each patient by high coverage targeted sequencing. (B) Proportions of patients with mutations in *KRAS* (brown), *NRAS* (yellow) or both (gray) within the three infant B-cell precursor acute lymphoblastic leukemia subgroups. (C) Mutant allele frequency of *KRAS* (brown squares) or *NRAS* (yellow circles) mutations in each individual patient. Discovery cohort, n=42; validation cohort, n=82.](1041176.fig2){#f2-1041176}

Surprisingly, we observed that many iBCP-ALL patients had mutations in both *KRAS* and *NRAS*, or more than one (different) mutation in the same gene ([Figure 2A,C](#f2-1041176){ref-type="fig"}). To further analyze the biological contribution of *KRAS* and *NRAS* mutations, we calculated the MAF of individual mutations and observed that the majority of patients who had a single *RAS* mutation (either *KRAS* or *NRAS*) had MAF scores between 0.20 and 0.45, suggesting that the mutation is present in a major leukemic subclone (*P*=0.0025). By contrast, those patients harboring two or more *RAS* mutations displayed MAF scores between 1% and 20%, compatible with these *RAS* mutations being in distinct and smaller leukemic subclones. We then analyzed the impact of *RAS* mutations on disease outcome and found no clinical correlation of *RAS* mutations with either clinical outcome (overall survival, event-free survival, central nervous system infiltration) or diagnostic parameters (gender, age, percentage of blasts and white blood cells) (*Online Supplementary Figure S5*).

Evidence of clone selection and genomic instability at relapse
--------------------------------------------------------------

Paired diagnostic-relapse samples were available for eight MLL-AF4^+^ iBCP-ALL patients, permitting longitudinal studies. Whole-exome sequencing revealed an 8-fold increase in the number of somatic non-synonymous mutations at relapse (19.5 mutations/patient, range:1-434, paired *t*-test *P*=0.03) ([Figure 3A,B](#f3-1041176){ref-type="fig"} and *Online Supplementary Table S3*). We performed orthogonal validation for 160 random mutations, and 90% and 75% of mutations with MAF \>15% and \<15%, respectively, were confirmed (*data not shown*). Similarly to diagnosis, the majority of the somatic mutations found at relapse had MAF commonly \<30%, suggesting the existence of multiple leukemic sub-clones ([Figure 3A](#f3-1041176){ref-type="fig"}). Importantly, none of the new *de novo* somatic mutations found at relapse was found in more than one patient, likely reflecting an intrinsic genomic instability of leukemic clones surviving induction/consolidation chemotherapy. This is further reflected by a significant enrichment of signature 6 associated with defective DNA mismatch repair, including a higher number of small indels, observed in MLL-AF4^+^ patients at relapse (*Online Supplementary Figure S6A*).

![Clonal evolution and genomic instability at relapse. (A) Total number of mutations identified for each patient in paired diagnostic-relapse samples. Total number of non-synonymous mutations (yellow area, right Y axis) and mutant allele frequency (MAF) for each mutation (individual dots, left Y axis) are represented for paired diagnostic and relapsed (R) samples. (B) Circos plot representation of the total number of mutations identified at diagnosis and relapse for a representative patient (MA4_17). Genomic rearrangements are represented by lines connecting both breakpoints. Copy number alterations (blue=gains, red=losses) are represented by the outer gray circle. Somatic mutations (both single nucleotide variants and indels) are depicted in the center of the circle and the affected gene is indicated. (C) Graphic representation of clonal evolution in paired diagnostic (DX)-relapsed (RL) samples. The number of unique somatic mutations called at diagnosis (orange), relapse (yellow) or shared between DX and REL (red) are indicated. Bigger gene names indicate higher MAF for the mutations shared at DX and REL. (D) Dynamics of RAS-mutated clones identified as MAF in matched DX-Remission-REL trios (n=8).](1041176.fig3){#f3-1041176}

To delineate the evolutionary clonal structure from diagnosis to relapse, we performed high-coverage targeted sequencing on the identified mutations in paired diagnostic-remission-relapse samples.^[@b37-1041176]^ Importantly, the main leukemic clone at relapse was always present at diagnosis although in some cases with a very low MAF, suggesting a chemotherapy-induced clonal pressure selecting for resistant/adapted leukemic subclones ([Figure 3C](#f3-1041176){ref-type="fig"}). Interestingly, we found a correlation between the number of mutations and time to relapse in MLL-AF4^+^ patients, with a trend towards a higher mutational load in patients with late relapses (*Online Supplementary Figure S6B*). We next analyzed the clonal evolution of *RAS*-mutated leukemic clones at relapse. We found that the contribution of the *RAS* mutations varied among patients: one-third of the iBCP-ALL patients had *RAS*-mutated clones at relapse (MA4_20 and MA4_22 increased the size of the *RAS*-mutated initial clone and in MA4_14 a *de novo RAS* mutation emerged), whereas it was lost in two-thirds of the patients (MA4_17, MA4_18, MA4_23, MA4_24) ([Figure 3D](#f3-1041176){ref-type="fig"}). This indicates that infants with MLL-AF4^+^ BCP-ALL relapse irrespective of the status of *KRAS* and *NRAS*. Thus, subclones carrying *KRAS* mutations do not exert an advantage over non-mutated clones, despite representing a recurrent genetic insult at diagnosis. Hence, this would argue against a leukemia-initiating role for RAS mutations.^[@b38-1041176]^ Alternatively, RAS mutations might indeed be leukemogenic drivers, but the treatment-induced genetic instability observed at relapse may compensate *de novo RAS* mutations, acting as new leukemia drivers cooperating with MLL-AF4 during relapse.

HOXA cluster genes are only expressed in t(4;11)^+^ patients expressing the reciprocal fusion *AF4-MLL* which determines clinical outcome
-----------------------------------------------------------------------------------------------------------------------------------------

To gain insights into the mechanisms underlying leukemogenesis in these mutationally silent *MLLr* and *MLL* germline iBCP-ALL patients, we performed RNA-sequencing in the discovery cohort of patients (n=42) using FL-derived CD34^+^CD19^+^ healthy B-cell progenitors as controls, as these cells most likely represent the healthy counterparts of the leukemic blast stalled at the pro/pre-B-cell differentiation stage. We first surveyed the expression of the genes previously reported to be specific to either *MLLr* iBCP-ALL or specifically to MLL-AF4^+^ iBCP-ALL^[@b39-1041176]^. RNA-sequencing profiling confirmed that these genes segregate patients according to the molecular subtype, MLL-AF4^+^, MLL-AF9^+^ and *MLL* germline (*Online Supplementary Figure S7*). We also observed, at diagnosis, a strong upregulation of the *MLL* target genes *FLT3*,^[@b40-1041176]^ *MEIS1*, *PROM1* and *HOXA* genes in many of our *MLLr* iBCP-ALL samples but not in *MLL* germline samples (*t*-test, *P*\<0.05) ([Figure 4A](#f4-1041176){ref-type="fig"}), thus validating our RNA-sequencing approach.

![Transcriptional signature of infant B-cell precursor acute lymphoblastic leukemia samples. (A) Heatmap representing *FLT3*, *PROM1*, *MEIS1* and *HOXA* gene expression according to the infant B-cell precursor acute lymphoblastic leukemia (iBCP-ALL) cytogenetic group and RAS mutations. (B) Top panel: heatmap showing HOXA cluster gene expression according to the expression of the reciprocal fusion *AF4-MLL*. Bottom panel: quantitative polymerase chain reaction validating high expression of *HOXA* cluster genes in t(4;11) iBCP-ALL patients expressing AF4-MLL. (C,D) Four-year event-free survival (C) and overall survival (D) Kaplan-Meier curves for t(4;11) iBCP-ALL patients according to *AF4-MLL* expression, n=43 t(4;11)^+^ patients. (E) Heatmap representation of selected genes for the signaling pathways most significantly deregulated. Right panels represent positive pathway enrichment called by gene set enrichment analysis software. Total 42 patients: 27 t(4;11)^+^, 5 t(9;11)^+^ and 10 MLLwt.](1041176.fig4){#f4-1041176}

Strikingly, the reciprocal AF4-MLL fusion gene was discernibly expressed in 19/43 (45%) of the t(4;11)+ iBCP-ALL samples, and its expression was always maintained at relapse (*data not shown*). We then compared the genes differentially expressed between AF4-MLL-expressing and non-expressing t(4;11)^+^ patients and found a striking positive correlation between the expression of the *HOXA* gene cluster and overexpression of the reciprocal AF4-MLL fusion (*t*-test, *P*=0.002) ([Figure 4B](#f4-1041176){ref-type="fig"}). These AF4-MLL/HOXA-expressing patients (n=19) had a significantly better prognosis than those lacking AF4-MLL/HOXA expression (n=24). Four-year event-free and overall survival rates were 62.4% (SE, 11.3%) *versus* 11.7% (SE, 10.2%) (*P*=0.001) ([Figure 4C](#f4-1041176){ref-type="fig"}), and 73.7% (SE, 10.1%) *versus* 25.2% (SE, 10.3%) (*P*=0.016) ([Figure 4D](#f4-1041176){ref-type="fig"}), respectively. When "AF4-MLL expression" was analyzed in a Cox model adjusting for risk stratification (medium risk or high risk according to the Interfant-06 protocol based on age at diagnosis, white blood cell count and response to prednisone), it retained its prognostic significance with a hazard ratio for patients lacking AF4-MLL expression of 3.42 \[95% confidence interval (95% CI): 1.35-8.63; *P*=0.01) compared to those expressing AF4-MLL/HOXA, while risk group was not significant (HR for high risk *vs*. medium risk, 1.34; 95% CI: 0.59-3.03; *P*=0.49). This is the first study showing that AF4-MLL overexpression correlates very well with transcriptional deregulation of the HOXA gene cluster in iBCP-ALL and that the co-expression of *AF4-MLL* and HOXA gene cluster identifies a subgroup of t(4;11)^+^ iBCP-ALL with a very more favorable clinical outcome.

We next explored new molecular pathways involved in the pathogenesis of iBCP-ALL, by performing an unbiased transcriptional analysis of the RNA-sequencing data from the iBCP-ALL patients. We found deregulated expression of a total of 3,905 genes, of which 2,575 (66%) were upregulated and 1,330 (34%) downregulated as compared with those of healthy FL-derived B-cell progenitors, illustrating the global transcriptional activation nature of *MLL* fusions (*Online Supplementary Figure S8*).^[@b25-1041176],[@b41-1041176]^ Furthermore, a significant upregulation of genes involved in the control of cell growth, including the CDK inhibitors *P21*, *P16*, *P19*, *P27* and components of the transforming growth factor-β pathway such as *TGFB1*, *SMAD* and *ACVR1B*, was observed in iBCP-ALL ([Figure 4D](#f4-1041176){ref-type="fig"} and *Online Supplementary Figure S9*). By contrast, iBCP-ALL showed a robust downregulation of genes involved in DNA integrity checkpoints such as *CHEK1*, *CHEK2*, *ATM*, *ATR* and *RAD17*, and in double-strand break repair genes including *ERCC4*, *BRCA1*, *POLA1* and *RAD51* ([Figure 4E](#f4-1041176){ref-type="fig"} and *Online Supplementary Figure S9*). These transcriptional changes were validated by quantitative reverse transcriptase polymerase chain reaction in ten patients per group (*Online Supplementary Figure S10*). Deregulation of DNA integrity checkpoints and double-strand break repair genes may well contribute to the genomic instability observed at relapse, and might explain the enrichment in C\>T/G\>A transitions, associated with the spontaneous deamination of 5-methylcytosine (*Online Supplementary Figures S3 and S6*).

By using FL-derived normal B-cell progenitors as controls, differences between leukemic blasts and their normal counterparts could be identified but this does not allow the definition of transcriptomic differences within the iBCP-ALL cytogenetic groups. We, therefore, analyzed the RNA-sequencing data comparing the genes differentially expressed in MLL-AF4^+^ *versus* MLL-AF9^+^ and MLL-wildtype iBCP-ALL patients, without considering normal B-cell progenitors as controls. A gene ontology analysis (gene set enrichment analysis, GSEA) performed with the genes differentially expressed revealed that MLL-AF4^+^ patients show, as compared to both MLL-AF9^+^ and MLL-wildtype patients, a significant upregulation of genes associated with cellular catabolism, coupled to a significant downregulation of negative regulators of the PI3-MAPK pathway, as well as of genes involved in lymphoid differentiation and RNApol II transcriptional regulation ([Figure 5](#f5-1041176){ref-type="fig"}). This suggests, respectively, a metabolic change in MLL-AF4^+^ cells towards rapid energy generation while reinforcing the basal hyperactivation of the PI3-MAPK pathway by *RAS* mutations ([Figures 1](#f1-1041176){ref-type="fig"} and [2](#f2-1041176){ref-type="fig"}), a poorly differentiated cellular origin of t(4;11), and an impairment of the normal function of AF4, a key component of the RNApol II transcription complex.

![Specific transcriptional differences between MLL-AF4^+^ and MLL-AF9^+^ or MLLwt infant B-cell precursor acute lymphoblastic leukemia patients. Here, FL-derived CD34^+^CD19^+^ progenitors were not included as normalizers in the analysis in order to avoid potential bias. Gene set enrichment analysis (GSEA) was performed with the genes differentially expressed between MLL-AF4^+^ patients and MLL-AF9^+^ or MLLwt patients. MLL-AF4^+^ infant B-cell precursor acute lymphoblastic leukemia (iBCP-ALL) patients showed a significant overexpression of genes associated with cellular catabolism, coupled to a significant downregulation of negative regulators of the PI3-MAPK pathway, as well as of genes involved in lymphoid differentiation and RNApol II transcriptional regulation as compared to both MLL-AF9^+^ and MLLwt iBCP-ALL patients. The bottom panels represent positive pathway enrichment called by GSEA software. Total 42 patients: 27 t(4;11)^+^, 5 t(9;11)^+^ and 10 MLLwt.](1041176.fig5){#f5-1041176}

Deep-sequencing analysis of B-cell receptor repertoires suggests a hematopoietic stem cell/early pre-VDJ progenitor as the cell-of-origin for t(4;11) and *RAS* mutations
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We next analyzed BCR repertoires to gain insights into the immunoglobulin heavy chain (IgH) rearrangement clonal composition of paired diagnostic-relapse samples from t(4;11)^+^ iBCP-ALL (4 pairs). BCR are generated through DNA recombination during B-cell differentiation and represent unique markers for each B-cell clone. Because the BCR sequence provides a molecular tag for each B-cell clone, high-throughput sequencing of BCR provides a detailed analysis of B-cell population dynamics and clone tracking.^[@b42-1041176],[@b43-1041176]^ BCR sequencing was therefore performed to address whether t(4;11)^+^ iBCP-ALL cells expressed fully rearranged BCR from which increased levels of B-cell clonal expansion may be observed and to determine whether there are detectable levels of B-cell clonal persistence over time indicative of B-cell clonal survival. BCR sequencing was performed on t(4;11)/MLL-AF4^+^ iBCP-ALL peripheral blood samples (blasts \>98%) using a polymerase chain reaction-based method^[@b37-1041176]^ with additional incorporation of unique molecular barcodes, allowing for accurate quantitation of relative B-cell clone frequency. After BCR sequence filtering, each sample yielded between 1,583-46,863 BCR (1,213-38,426 unique BCR) (*Online Supplementary Table S5*).

We first delineated the relative clonality in these patients, and found that the BCR repertoires from t(4;11)^+^ patients did not exhibit significantly expanded VDJ-rearranged B-cell clones ([Figure 6A](#f6-1041176){ref-type="fig"}) either at diagnosis or relapse compared to healthy peripheral blood samples ([Figure 6B](#f6-1041176){ref-type="fig"}). This is in contrast to non-MLL BCP-ALL patients (n=5) including three patients with t(1;19)/TCF3-PBX1 (EF2-PBX1), one with t(12;21)/ETV6-RUNX1 (TEL-AML1) and one with t(9;22)/BCR-ABL1, which were all found to be significantly clonal, with large B-cell clones comprising \~3-40% of total BCR ([Figure 6B,C](#f6-1041176){ref-type="fig"}).^[@b37-1041176]^ Given the persistence of both t(4;11) and *RAS* mutations in MLL-AF4^+^ iBCP-ALL, the lack of B-cell clonal expansion or persistence supports the model that t(4;11)/MLL-AF4^+^ iBCP-ALL malignant cells are developmentally stalled at the pro-B stage, and that the cellular origin of such genomic drivers has to be pre-VDJ stem/progenitor cells.

![Analysis of B-cell receptor repertoires suggest a hematopoietic stem cell/early pre-VDJ progenitor as the cell-of-origin for t(4;11)/MLL-AF4^+^ infant B-cell precursor acute lymphoblastic leukemia. (A) Cloud-plots of B-cell receptor (BCR) repertoires from two representative t(4;11)^+^ infant B-cell precursor acute lymphoblastic leukemia (iBCP-ALL) patients depicting the existence of many minor non-expanded B-cell clones either at diagnosis or relapse. Each vertex represents a unique BCR sequence, and the relative vertex size is proportional to the number of identical reads. (B) Largest BCR clone size in t(4;11)^+^ iBCP-ALL, healthy individuals and non-t(4;11)^+^ pediatric BCP-ALL. (C) Cloud-plots of BCR repertoires of representative t(1;19)/E2A-PBX1^+^, t(12;21)/TEL-AML1^+^ and t(9;22)/BCR-ABL^+^ patients showing high clonality of B-cell clones. The samples from the iBCP-ALL patients who were BCR-sequenced were four MLL-AF4^+^ diagnostic-relapse pairs, three E2A-PBX1^+^ samples, one TEL-AML1^+^ sample and one BCR-ABL^+^ sample.](1041176.fig6){#f6-1041176}

Finally, in order to understand whether the fetal cell-of-origin in iBCP-ALL lies upstream of committed B progenitors, we compared the transcriptome of iBCP-ALL blasts (n=42) with that of highly purified human FL HSPC populations (3-7 for each population) ([Figure 7A,B](#f7-1041176){ref-type="fig"} and *Online Supplementary Table S6*) by RNA-sequencing. In keeping with the results of the BCR analysis, our principal component analysis revealed a gene expression signature for primitive Lin^−^CD34^+^CD38^−^CD19^−^ FL HSPC (hematopoietic stem cells, multipotent progenitors, and lymphoid-primed multipotent progenitors, which lie upstream of B progenitors) very similar to t(4;11)^+^ iBCP-ALL, while FL-committed B progenitors clustered as a transcriptionally different entity ([Figure 7C](#f7-1041176){ref-type="fig"}).

![Comparison of the transcriptome of human fetal CD34^+^ hematopoietic stem and progenitor cell populations to infant B-cell precursor acute lymphoblastic leukemia. (A) Schematic representation of B-cell development in human fetal liver (FL) showing immunophenotypic definitions for hematopoietic stem cells (HSC), multipotent progenitors (MPP), lymphoid-primed multipotent progenitors (LMPP), committed B progenitors (CBP) and B cells. The onset and expected patterns of IgH rearrangements^[@b59-1041176],[@b60-1041176]^ are depicted as red arrows. (B) Sorting strategy for FL hematopoietic stem and progenitor (HSPC) populations by fluorescence-activated cell sorting. The sorting gates for each population are shown in representative flow plots on the left. The purity of the sorted populations is depicted on the right demonstrating \>95% purity. (Lin, Lineage cocktail). (C) Principal component analysis of gene expression of infant B-cell precursor acute lymphoblastic leukemia (iBCP-ALL) samples (n=42) and FL HSPC populations (n=3-7) using the top 1,000 variably expressed genes, as determined by RNA-sequencing. FL HSPC as in (A); MAF4, MLL-AF4^+^ iBCP-ALL; MA9, MLL-AF9^+^ iBCP-ALL; MLLwt, MLL wildtype iBCP-ALL.](1041176.fig7){#f7-1041176}

Discussion
==========

We set out to perform multi-layered sequencing on a large cohort iBCP-ALL patients, all enrolled in the international, collaborative Interfant treatment protocol. The fact that all patients were identically treated provides legitimacy and confidence in potential correlations of clinical value. Our study revealed an average of 2.5 non-silent single nucleotide variants, a 2-fold higher number than that reported by Andersson *et al*.,^[@b20-1041176]^ likely reflecting the 3-fold larger sequencing coverage. This silent mutational landscape, even in non-MLL iBCP-ALL, likely reflects the very young age of these patients, reinforcing the notion that infant cancer is a developmental disease with not enough time to develop somatic mutations. We also found the only recurrent, but subclonal, mutations occur in the *KRAS* and *NRAS* genes (gain-of-function mutations), although the frequency of subclonal *NRAS* mutations is significantly higher in t(4;11)^+^ patients. In line with our previous work we found no recurrent mutations in the *FLT3* gene.^[@b40-1041176]^

Analysis of clonal evolution of *RAS*-mutated clones from diagnosis to relapse revealed that one-third of the patients still carry *RAS* mutations at relapse, whereas the other two-thirds of patients who relapse have lost the diagnostic *RAS* mutation. This is in accordance with recently published data by Trentin *et al*.,^[@b36-1041176]^ and suggests that the therapy is able to eliminate the *RAS*-mutated clone in some patients, while in other patients the *RAS* mutation seems to confer chemoresistance, allowing these clones to evade treatment.^[@b44-1041176]^ Intriguingly, \~25% of the patients carry more than one *RAS*-mutated clone at diagnosis, indicating a selection bias towards mutations in the *RAS* genes, or activated RAS pathways during leukemic transformation. From this perspective, the occurrence of patients carrying multiple distinct clones with activated RAS pathways may point to convergent evolution of clones capable of controlling the proliferation rate. However, arguing against this is the substantial representation of patients not carrying *RAS* mutations at all. Hence, the role of *RAS* mutations in t(4;11)^+^ iBCP-ALL remains obscure, and the available data suggest that RAS pathway mutations are unlikely leukemia-initiating lesions. Indeed, Tamai *et al*.^[@b45-1041176]^ showed that leukemogenesis of transgenic mice expressing human MLL-AF4 could be significantly accelerated by *KRAS* mutations. However, although activated *KRAS* did cooperate with MLL-AF4 in human cord blood-derived CD34^+^ HSPC to promote extramedullary infiltration and central nervous system infiltration it failed to initiate leukemia in engrafted mice.^[@b27-1041176]^ Importantly, we report a lack of correlation between *RAS* status and parameters associated with diagnosis or disease outcome such as overall survival, event-free survival, central nervous system infiltration, gender, percentage of blasts and white blood cells and age, further supporting the concept that RAS mutations are not leukemia-initiating/propagating lesions.

Clearly, this brings us back to the central question of whether or not MLL-AF4 by itself is sufficient to initiate BCP-ALL in humans. The silent mutational landscape observed in this study and by others^[@b20-1041176]^ certainly votes in favor of MLL-AF4^+^ iBCP-ALL being initiated by a single "big-bang" transformation hit, probably in a short-lived but highly proliferative prenatal B-cell progenitor.^[@b4-1041176]^ This hypothesis is supported by recent work by Lin *et al*., who indeed demonstrated that enforced expression of a fusion transcript consisting of human *MLL* and murine Af4 in cord blood-derived CD34^+^ HPSC is sufficient to induce pro-B ALL in xenografted immunodeficient mice.^[@b21-1041176],[@b22-1041176]^ Yet, similar results using a human MLL-AF4 transcript remain to be established.

Although MLL-AF4 by itself may be sufficient to induce BCP-ALL without significant contributions from cooperative genetic lesions, the contribution of the *MLL-AF4* and RAS mutations to leukemogenesis should take into account the nature of both the fetal target cell for transformation and the leukemia-initiating cell, according to the increasingly accepted stochastic stem cell model of BALL.^[@b46-1041176],[@b47-1041176]^ Here, we employed high-throughput BCR-sequencing of the IgH locus to delineate the dynamics of clonality of B-cell populations in paired diagnosis-relapse samples of t(4;11)/MLL-AF4^+^ iBCP-ALL. While pediatric patients with E2A-PBX1^+^, TEL-AML1^+^ and BCR-ABL1^+^ BALL all had significantly clonal disease, with a major VDJ rearranged B-cell IgH clone accounting for up to 40% of all BCR, infants with MLL-AF4^+^ BCP-ALL exhibited a BCR repertoire composed of thousands of minor, non-expanded VDJ rearranged IgH B-cell clones. Because *MLL* fusions are clonal and *RAS* mutations are found in clones of relative big size, this suggests that *MLL* fusions with or without *RAS* mutations are likely to originate in primitive fetal progenitors that have a germline or an incompletely rearranged (DJ) IgH locus.^[@b48-1041176]^ Indeed, an unsupervised comparison of the transcriptome of FL HSPC populations and iBCP-ALL blasts suggests that while the gene expression of primitive FL HSPC (Lin^−^CD38^−^CD34^+^CD19^−^ populations) is similar to that of iBCP-ALL, FL B progenitors (CD34^+^CD19^+^) are transcriptionally distinct. Our data elegantly reinforces previous fluorescence *in-situ* hybridization findings suggesting that a primitive "pre-VDJ" stem/progenitor cell (perhaps CD34^+^CD19^−^) may represent the cell in which both t(4;11) and *RAS* mutations arise.^[@b14-1041176],[@b31-1041176],[@b49-1041176]^

Cooperative leukemogenic events in iBCP-ALL may need to be sought beyond genetic insults; for instance, epigenetic and transcriptomic deregulation. MLL-AF4 might only induce BCP-ALL in cells that meet certain epigenetic and transcriptomic make-up criteria, either influenced by microenvironmental cues, or characteristic of the cell-of-origin.^[@b31-1041176]^ Indeed, lesions such as RAS mutations may contribute to disease pathogenesis only against certain intrinsic epigenetic or transcriptomic backgrounds present in the cell in which the *MLL* translocations occurred^[@b50-1041176],[@b51-1041176]^. This is supported by the limited impact of *RAS* mutations in transcriptomic signatures associated with leukemia origin, development and pathogenesis, although this is likely due to the subclonal nature of *RAS* mutations.^[@b38-1041176]^ However, in line with the reported contribution of RAS mutations to extramedullary infiltration of MLLr BCP-ALL blasts,^[@b27-1041176]^ *RAS*-mutated patients displayed a transcriptomic signature associated with migration.

The functional and molecular contribution of the reciprocal fusion genes resulting from the derivative translocated chromosomes remains obscure in cancer. The AF4-MLL genomic fusion was previously detected in 80-85% of t(4;11)^+^ patients.^[@b5-1041176],[@b52-1041176]^ Our "multi-layered omics" approach allowed for the exact characterization of the t(4;11) molecular DNA/RNA break points and the identification of those patients expressing the reciprocal AF4-MLL fusion. We now report that the AF4-MLL reciprocal fusion is expressed in only 50% of t(4;11)^+^ iBCP-ALL patients. Strikingly, there was a previously unrecognized and very significant positive correlation between the upregulation of the *HOXA* gene cluster and the expression of AF4-MLL. Of note, a recent study showed that approximately half of t(4;11)^+^ patients do not have an activated HOXA signature.^[@b44-1041176],[@b53-1041176],[@b54-1041176]^ Furthermore, in the recent MLL-Af4-induced B-ALL xenograft model MLL-Af4 failed to bind to HOXA genes and therefore HOXA gene expression was not upregulated.^[@b21-1041176]^ This is experimentally supported by chromatin immunoprecipitation-sequencing analysis performed in human embryonic stem cells transduced with MLL-AF4, AF4-MLL or both showing a significant enrichment of H3K79 methylated regions specifically associated with *HOX-A* cluster genes in double fusion-expressing hematopoietic derivatives, establishing a functional and molecular cooperation between MLL-AF4 and AF4-MLL fusions during human hematopoietic development (*data not shown*). Strikingly, AF4-MLL-expressing patients had a 5-fold longer event-free survival and a 3-fold longer overall survival compared to t(4;11)^+^ iBCP-ALL patients lacking AF4-MLL expression, which is in line with previous reports suggesting that high HOXA gene expression is associated with improved survival and lower risk of relapse.^[@b22-1041176],[@b39-1041176]^ Because the expression of AF4-MLL is not analyzed in routine molecular diagnosis, our "multi-layered omics" approach was critical to unraveling the association between AF4-MLL and HOXA expression, thus identifying a novel subgroup of t(4;11)^+^ iBCP-ALL with better clinical outcome. It is very important for routine diagnostic and clinical practice that when the expression of AF4-MLL was evaluated in a Cox model adjusting for risk stratification (medium risk or high risk according to the Interfant-06 protocol), it retained its prognostic significance.

Mechanistically, AF4-MLL contains the SET domain disrupted from its "specification domain", the N-terminal portion of MLL, which binds to MEN1 and LEDGF thus shaping the gene-targeting module of the MLL gene. When AF4-MLL is expressed, the N-terminal portion is substituted by the AF4 N-terminus (AF4N) which is the crucial domain for binding to and strongly activating RNA polymerase II (RNAP II) for transcriptional elongation. Thus, expression of A4M-MLL may induce robust RNAP II-dependent gene transcription by overwriting the elongation control process in a dominant fashion.^[@b55-1041176]--[@b58-1041176]^ We hypothesize that a likely function of AF4-MLL could be to prepare the ground for MLL-AF4 or other transcription factors to skew normal and leukemic hematopoietic cell fate decisions. This also explains why MLL-AF4, but not AF4-MLL, seems to be necessary in 100% of patients.

Despite being a developmental cancer, iBCP-ALL patients did not show reactivation of pluripotent or embryonic-like gene expression signatures as revealed by RNA-sequencing. Additional research is required to decipher the nature of the insults initiating *MLLr* iBCP-ALL, as so far we can only speculate on the data currently available. Whole-genome pyrosequencing will likely provide unique insights into the DNA methylome landscape of this mutationally silent iBCP-ALL. This study has clinical implications in the diagnostic risk-stratification of t(4;11)^+^ iBCP-ALL.
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